2026
Tilbage 2026 MipSalus Receives Approval from DKMA to Initiate First-in-Human Clinical Study for Phelimin, a Novel Treatment for Phenylketonuria (PKU). Hørsholm, Denmark – Wednesday, June 17, 2026 The Danish Medicines Agency (DKMA) has approved an application from MipSalus to initiate a clinical phase 1 study with the title: A phase 1 first-in-human study of a […]
2025
Tilbage 2025
2014
Tilbage 2014 MipSalus receives a grant to develop a breakthrough treatment of PKU February 2014: Højteknologifonden (now: Innovation Fund Denmark) has selected MipSalus for a DKK 13 million grant. With the grant, MipSalus will continue the development of the company’s breakthrough treatment for the orphan disease Phenylketonuria (PKU) in close collaboration with Aarhus University, Denmark.
2016
Tilbage 2016 MipSalus is granted an Orphan Drug Designation for Phelimin from EMA November 2016: On October 6, based on scientific evidence produced by MipSalus, the European Medicines Agency (EMA) announced that MipSalus’ Phelimin has potential as treatment of Phenylketonuria (PKU). Following the announcement, the European Commission granted Phelimin an Orphan Drug Designation on November 18, 2016. The EU orphan designation […]
2017
Tilbage 2017 Collaboration with Liverpool University and The Royal Liverpool University Hospital September 2017: Together with Liverpool University and The Royal Liverpool University Hospital, Mipsalus has conducted a series of mice studies which indicate that Phelimin can very likely be used to treat children and adolescents suffering from Alkaptunoria (AKU) – a rare inborn error of amino […]
2018
Tilbage 2018 MipSalus selected for a grant for resource recycling in medicine production November 2018: MipSalus has received a DKK 3 million grant from the Ministry of Environment and Food of Denmark’s Eco-Innovation Program, MUDP. The grant will be used to develop a concept for optimization of resource recycling in new Danish medicinal product production. MipSalus’ […]
2019
Tilbage 2019 Copenhagen Nanomedicine Day November 2019: Attending the Copenhagen Nanomedicine Day at University of Copenhagen, CSO Klaus Gregorius will give a talk on how MipSalus uses phenylalanine-binding polymer nano-particles as a medicinal product for the treatment of PKU patients. The 33rd E.S.PKU Conference November 2019: MipSalus attends the 33rd E.S.PKU (European Society for Phenylketonuria and […]
2020
Tilbage 2020 MipSalus closes a private placement November 2020: MipSalus closes a private placement from private investors. Inborn Errors of Metabolism Drug Development Conference March 2020: CSO Klaus Gregorius will present MipSalus’ groundbreaking yet simple solution to treating PKU at the Inborn Errors of Metabolism Drug Development Conference. With the new treatment which MipSauls is currently developed, […]
2021
Tilbage 2021 Additional facilities April 2021: Once again, MipSalus expands its premises in DTU Science Park. The expansion includes laboratories, storage capacity and an additional office. The new premises will primarily be used for establishing a facility for demonstration and documentation of scalable production methods for Phelimin. Grant for circular economy in medicine production March 2021: […]
2022
Tilbage 2022 MipSalus forms a consortium comprising three of Europe’s leading PKU clinics January 2022: In preparation for planning and conducting the upcoming clinical trials, MipSalus has built a consortium of PKU clinics in Europe comprising Rigshospitalet in Denmark, The University Hospitals Birmingham in the United Kingdom, and The Mater Hospital in Ireland.